



Invitation
20 Annual
26 General Meeting

of PolyPeptide Group AG

8 April 2026
16.00 (CEST)

doors open at 15.30 (CEST)

Chollerhalle, Chamerstrasse 177
6300 Zug, Switzerland

Letter to Shareholders

Dear Shareholders,

On behalf of the Board of Directors, I am pleased to share with you the invitation to the fifth annual General Meeting of PolyPeptide Group AG which will be again held at the Chollerhalle in Zug on 8 April 2026 ("**AGM 2026**").

2025 was a year of strong progress for PolyPeptide. We delivered strong revenue growth and a marked improvement in profitability, reflecting disciplined execution and a clear strategic focus. We strengthened our industrial-scale capabilities, advanced key expansion projects across our global network, and continued to translate growing customer demand into sustainable performance. At the same time, we strengthened our financial and operational foundation, ensuring that growth is supported by a resilient and capital-efficient business model.

PolyPeptide operates in a dynamic and fast-growing market, where peptide-based therapies are gaining importance across an expanding range of therapeutic areas. We continue to deepen our position in the field of metabolic therapeutics, supported by a robust portfolio of late-stage and commercial projects. This broad and diverse demand underpins our confidence in the durability of our growth and the strategic relevance of our capabilities.

Alongside commercial momentum, we continued to invest in innovation and sustainability. These efforts reinforce our ambition to be the most innovative peptide CDMO, well positioned for long-term value creation.

We would like to extend a big thank you to our shareholders for continuing to support our growth strategy. We count on your active participation at the AGM 2026 and look forward to welcoming you in person at the Chollerhalle in Zug on 8 April 2026.

Yours sincerely,

Peter Wilden
Chair of the Board of Directors

Baar, 17 March 2026

Agenda and proposals

(English translation of the binding German original; references to PolyPeptide Group AG's (the "Company") website are to www.polypeptide.com/investors/results-center/results-2025/)

1. Votes on the financial and non-financial reporting for the financial year 2025

1.1. Approval of the Management Report, Statutory Financial Statements and Consolidated Financial Statements, in each case, for the financial year 2025

Proposal: The Board of Directors proposes that the General Meeting approves the Management Report, Statutory Financial Statements and Consolidated Financial Statements, in each case, for the financial year 2025.

Explanations: According to art. 698 para. 2 items 3 and 4 of the Swiss Code of Obligations ("CO") and the Company's Articles of Association, the General Meeting is responsible for approving the Management Report, Statutory Financial Statements and Consolidated Financial Statements. Approval of the Statutory Financial Statements and Consolidated Financial Statements is required for the resolution on the appropriation of accumulated deficit. The Statutory Auditors, BDO AG (Zurich), have audited the Statutory Financial Statements of PolyPeptide Group AG and the Consolidated Financial Statements of PolyPeptide Group AG and its consolidated subsidiaries, in each case, for the financial year 2025, and recommend them for approval. The Management Report, the Statutory Financial Statements and Consolidated Financial Statements, in each case, for the financial year 2025 and the Auditors' Reports are part of the Annual Report 2025 and available online on the [Company's website](#).

1.2. Consultative vote on the Remuneration Report 2025

Proposal: The Board of Directors proposes that the General Meeting approves the Remuneration Report 2025 contained in the Annual Report 2025 in a consultative vote.

Explanations: In accordance with art. 735 para. 3 item 4 CO and the Company's Articles of Association, if variable remuneration that the members of the Board of Directors and Executive Committee directly or indirectly receive from the Company is voted on prospectively, the Remuneration Report must be submitted to the General Meeting for a consultative vote.

The General Meeting held on 10 April 2024 voted prospectively on the maximum aggregate compensation of the Executive Committee (fixed and variable components) for the financial year 2025. The Board of Directors did not receive any variable compensation in the financial year 2025.

The Remuneration Report 2025 describes the Company's remuneration governance and principles, structure and elements. The Statutory Auditors, BDO AG (Zurich), have audited the Remuneration Report 2025. The Remuneration Report 2025, including the Auditors' Report, is part of the Annual Report 2025 and

available online on the [Company's website](#).

1.3. Approval of the report on non-financial matters for the financial year 2025

Proposal: The Board of Directors proposes that the General Meeting approves the report on non-financial matters for the financial year 2025 contained in the Annual Report 2025.

Explanations: According to art. 964c para. 1 CO and the Company's Articles of Association, the General Meeting is responsible for approving the report on non-financial matters. The report on non-financial matters for the financial year 2025 comprises selected sections from the Company's Sustainability Report 2025. These sections are specified in the chapter "Index of disclosure requirements in accordance with art. 964b Swiss Code of Obligations" of the Sustainability Report 2025 and contain the non-financial information required under art. 964b CO, including PolyPeptide's Climate Report based on the Taskforce on Climate-related Financial Disclosure (TCFD) recommendations. The Sustainability Report 2025 further includes an independent practitioner's limited assurance report by BDO AG (Zurich) on the Sustainability Report 2025. The report on non-financial matters for the financial year 2025 is part of the Annual Report 2025 and available online on the [Company's website](#).

2. Granting discharge to the members of the Board of Directors and Executive Committee

Proposal: The Board of Directors proposes that the General Meeting grants discharge from liability to all members of the Board of Directors and Executive Committee in office in the financial year 2025 for their activities in the financial year 2025.

Explanations: Pursuant to art. 698 para. 2 item 7 CO and the Company's Articles of Association, the General Meeting is responsible for the discharge resolution. With the discharge of the members of the Board of Directors and Executive Committee that were in office in the financial year 2025, the Company and the approving shareholders declare that they will not hold them accountable for events from the financial year 2025 that were brought to the attention of the General Meeting. The Company is not aware of any facts that would oppose to a full discharge.

3. Appropriation of accumulated deficit

Proposal: The Board of Directors proposes that the General Meeting approves that the accumulated deficit of CHF 1,786,196,497 be carried forward to the new account.

Appropriation of the accumulated deficit (2025)	CHF
Accumulated deficit brought forward	-1,077,871,571
Net loss on sale of treasury shares	-1,534,319
Net loss for the year	-706,790,607
Accumulated deficit to be carried forward	-1,786,196,497

Explanations: Pursuant to art. 698 para. 2 item 4 CO, the General Meeting is responsible for passing resolutions on the appropriation of available earnings or the accumulated deficit. As per the end of the financial year 2025, the accumulated deficit amounts to CHF 1,786,196,497. It is proposed that such deficit be carried forward to the new account in accordance with art. 674 para. 2 CO.

4. Elections

4.1. Re-Election of the members of the Board of Directors

Proposal: The Board of Directors proposes that the General Meeting individually re-elects each of the following persons as members of the Board of Directors for a term of office ending at the conclusion of the next annual General Meeting:

4.1.1. Peter Wilden

4.1.2. Patrick Aebischer

4.1.3. Jane Salik

4.1.4. Erik Schropp

4.1.5. Philippe Weber

4.1.6. Jo LeCouilliard

Explanations: According to art. 710 para. 1 CO and the Company's Articles of Association, the current term of office of all members of the Board of Directors ends at the conclusion of the General Meeting on 8 April 2026 ("**AGM 2026**"). Pursuant to art. 698 para. 2 item 2 and art. 710 para. 1 and 3 CO and the Company's Articles of Association, re-election is possible and to be resolved by the General Meeting for each member of the Board of Directors individually. All current members of the Board of Directors are standing for re-election.

The composition of the Board of Directors should reflect the Company's objectives, strategic requirements, geographical reach and its culture. It should further be diverse in terms of, *inter alia*, gender, nationality, regional representation and business experience. With the proposed re-election of the members of the Board

of Directors, PolyPeptide will continue to uphold these principles and maintain a Board aligned with the criteria considered essential for strategic success. Based on the re-election of the proposed members of the Board of Directors, PolyPeptide considers the majority of its members to be independent and believes that its proposal is in the best interest of the Company.

The detailed biography of each candidate standing for re-election along with PolyPeptide's definition of independence and the status of each director, can be found in the Corporate Governance Report 2025, which is part of the Annual Report 2025, and available online on the [Company's website](#).

4.2. Re-Election of the Chair of the Board of Directors

Proposal: The Board of Directors proposes that the General Meeting re-elects Peter Wilden as Chair of the Board of Directors for a term of office ending at the conclusion of the next annual General Meeting, subject to his re-election as a member of the Board of Directors.

Explanations: According to art. 712 para. 1 CO and the Company's Articles of Association, the current term of office of the Chair of the Board of Directors ends at the conclusion of the AGM 2026. Pursuant to art. 698 para. 3 item 1 and art. 712 para. 1 and 3 CO and the Company's Articles of Association, re-election of the Chair of the Board of Directors is possible and to be resolved by the General Meeting. Dr. Wilden stands for re-election. The Board of Directors believes that Dr. Wilden is best suited for the role of Chair of the Board of Directors, and his re-election is in the best interest of the Company. The detailed biography of Dr. Wilden can be found in the Corporate Governance Report 2025, which is part of the Annual Report 2025, and available online on the [Company's website](#).

4.3. Re-Election of the members of the Remuneration and Nomination Committee

Proposal: The Board of Directors proposes that the General Meeting individually re-elects each of the following persons as members of the Remuneration and Nomination Committee for a term of office ending at the conclusion of the next annual General Meeting, subject to their re-election as members of the Board of Directors:

4.3.1. Philippe Weber

4.3.2. Peter Wilden

Explanations: According to art. 733 para. 3 CO and the Company's Articles of Association, the current term of office of all members of the Remuneration and Nomination Committee ends at the conclusion of the AGM 2026. Pursuant to art. 698 para. 3 item 2 and art. 733 para. 1 and 3 CO, re-election is possible and to be resolved by the General Meeting for each member of the Remuneration and Nomination Committee individually. All the current members stand for re-election. The Board of Directors believes that the re-election of the members of the Remuneration and Nomination Committee is in the best interest of the Company. The detailed biographies of both candidates can be found in the Corporate Governance Report 2025, which is part of the Annual Report 2025, and available

online on the [Company's website](#).

4.4. Re-Election of the Statutory Auditors

Proposal: The Board of Directors proposes that the General Meeting re-elects BDO AG, Schiffbaustrasse 2, 8005 Zurich, Switzerland, as Statutory Auditors for the financial year 2026.

Explanations: According to art. 730a para. 1 CO and the Company's Articles of Association, the term of office of the Company's Statutory Auditors ends with the approval of the Statutory Financial Statements for the financial year 2025. According to art. 698 para. 2 item 2 and art. 730 para. 1 CO and the Company's Articles of Association, the General Meeting is responsible for the election of the Statutory Auditors. Pursuant to art. 730a para. 1 CO and the Company's Articles of Association, re-election is possible. BDO AG fulfils the legal requirements and is available for re-election. The Board of Directors believes that BDO AG is well suited to continue serving as the Company's Statutory Auditors. More information about the Company's Statutory Auditors can be found in the Corporate Governance Report 2025, which is part of the Annual Report 2025, and available online on the [Company's website](#).

4.5. Re-Election of the Independent Proxy

Proposal: The Board of Directors proposes that the General Meeting re-elects ADROIT Attorneys, Kalchbühlstrasse 4, 8038 Zurich, Switzerland, represented by Mr. Roger Föhn, as Independent Proxy for a term of office ending at the conclusion of the next annual General Meeting.

Explanations: According to art. 689c para. 1 CO and the Company's Articles of Association, the current term of office of the Company's Independent Proxy ends at the conclusion of the AGM 2026. Pursuant to art. 698 para. 3 item 3 and art. 689c para. 1 CO and the Company's Articles of Association, re-election is possible and to be resolved by the General Meeting. ADROIT Attorneys fulfils the legal requirements and is available for re-election. The Board of Directors believes that the re-election of ADROIT Attorneys is in the best interest of the Company and ensures continuity.

5. Approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee

5.1. Approval of the maximum aggregate compensation of the Board of Directors

Proposal: The Board of Directors proposes that the General Meeting approves the maximum aggregate amount of compensation of the Board of Directors in the amount of CHF 1,600,000 (one million six hundred thousand) (including all employee and employer social security contributions) for a term of office ending at the conclusion of the next annual General Meeting.

Explanations: Pursuant to art. 698 para. 3 item 4 and art. 735 para. 3 CO and the Company's Articles of Association, the General Meeting shall approve the maximum aggregate amount of compensation of the Board of Directors for the term of office ending at the conclusion of the next annual General Meeting. This approval is a prospective and binding vote in accordance with the Company's Articles of Association. The principles of remuneration for the Board of Directors are described in art. 25 of the Company's Articles of Association and in the Remuneration Report 2025.

The Company's remuneration framework for the Board of Directors aims to be simple, clear and transparent. The proposed amount of CHF 1,600,000 has been calculated on the basis of the remuneration framework disclosed in the Remuneration Report 2025 for the members of the Board of Directors for the term of office ending at the conclusion of the next annual General Meeting. The proposed amount remains unchanged compared to the total amount approved by the annual General Meeting 2025 for the previous period.

The proposed amount includes the compensation for chair positions and memberships in Board committees. For the period until the next annual General Meeting, members of the Board of Directors will only receive fixed compensation elements, of which at least half will be payable in shares that are blocked for three years from the date of grant, and the remainder in cash. The compensation actually paid and / or awarded to the Board of Directors will be disclosed in the Remuneration Reports 2026 and 2027, respectively, both of which will be submitted for a consultative vote to the General Meeting.

For more detailed information on the Company's remuneration governance and principles, structure and elements, please refer to the Remuneration Report 2025, which is part of the Annual Report 2025, and available online on the [Company's website](#).

5.2. Approval of the maximum aggregate compensation of the Executive Committee

Proposal: The Board of Directors proposes that the General Meeting approves the maximum aggregate compensation of the Executive Committee (fixed and variable components) of CHF 7,000,000 (seven million) (including all employee and employer social security and pension contributions) for the financial year 2027.

Explanations: Pursuant to art. 698 para. 3 item 4 and art. 735 para. 3 CO and the Company's Articles of Association, the General Meeting shall approve the maximum aggregate amount of fixed and variable compensation for the Executive Committee that may be paid or allocated for the financial year 2027. This approval is a prospective and binding vote in accordance with Company's Articles of Association. The principles of remuneration for the Executive Committee are described in art. 26 of the Company's Articles of Association and in the Remuneration Report 2025.

The Company's remuneration framework for the Executive Committee aims to reward individual and collective performance aligned with shareholder interests within a simple, clear and transparent structure. The current remuneration framework for the Executive Committee consists of fixed compensation in cash as well as variable compensation elements. The fixed compensation comprises the base salary, pension and other benefits. The variable compensation comprises a short-term cash component and a long-term share-based component. For the long-term share-based component, the value of the awarded units at grant date is based on an assumption of 100% target achievement.

The proposed amount of CHF 7,000,000 has been calculated on the basis of the remuneration framework disclosed in the Remuneration Report 2025 for the Executive Committee. The proposed amount remains unchanged compared to the total amount approved by the annual General Meeting 2025 for the financial year 2026. It takes into consideration the base salaries for the Executive Committee, pension, other benefits and social security costs, amounts for variable compensation (*i.e.*, both short-term cash components and long-term share-based components; whereby for the long-term share-based component, the value of the awarded units at grant date is based on an assumption of 100% target achievement) as well as a reserve for unforeseen circumstances. The fixed and variable compensation actually paid and / or granted to the Executive Committee for the financial year 2027 will be disclosed in the Remuneration Report 2027, which will be submitted for a consultative vote to the General Meeting.

For more detailed information on the Company's remuneration governance and principles, structure and elements, please refer to the Remuneration Report 2025, which is part of the Annual Report 2025, and available online on the [Company's website](#).

Organizational notes

Date: Wednesday, 8 April 2026, 16.00 CEST (doors open at 15.30 CEST)
Form / Place: In-person AGM at the **Chollerhalle**, Chamerstrasse 177, 6300 Zug, Switzerland

Annual Report 2025

The Annual Report 2025, including the Management Report 2025, the Sustainability Report 2025 (of which selected sections comprise the report on non-financial matters for the financial year 2025), the Corporate Governance Report 2025, the Remuneration Report 2025, the Statutory Financial Statements 2025 and the Consolidated Financial Statements 2025 as well as the Auditors' Reports, is available online at www.polypeptide.com/investors/results-center/results-2025/.

Record Date for the share register, admission and voting cards

Only shareholders entered in the share register with voting rights by 31 March 2026, 17.00 (CEST), are entitled to exercise their voting rights at the AGM 2026. From 31 March 2026, 17.01 (CEST), to and including 8 April 2026, no entries will be made in the share register that would create a right to vote at the AGM 2026. Shareholders who sell part or all their shares prior to the AGM 2026 are no longer entitled to vote with respect to the shares sold.

Shareholders who wish to attend the AGM 2026 personally should return the enclosed reply form in the provided envelope by 2 April 2026 at the latest to: PolyPeptide Group AG, c/o areg.ch AG, Fabrikstrasse 10, 4614 Hägendorf, Switzerland. Upon due return of the completed reply form, the admission and voting cards will be sent by mail. Shareholders can find further guidance in the enclosed reply form.

Information about the voting results at the AGM 2026 will be published by media release following the AGM and will be available at www.polypeptide.com/news/events/general-meeting-2026/.

Exercise of voting rights and representation

Shareholders may be represented at the AGM 2026 by the Independent Proxy or by means of a written proxy by any other person of the shareholder's choice.

The annual General Meeting held in 2025 re-elected ADROIT Attorneys, Kalchbühlstrasse 4, 8038 Zurich, Switzerland, represented by Mr. Roger Föhn, as Independent Proxy. The enclosed reply form serves exclusively to grant power of attorney to the Independent Proxy. Shareholders wishing to be represented by the Independent Proxy are kindly requested to fill in the reply form and return it by mail using the enclosed envelope. Forms must be received by 7 April 2026. Please allow appropriate time for delivery.

Remote electronic voting, electronic order of admission and voting cards

Shareholders may optionally also issue electronic authorizations and instructions to the Independent Proxy and submit orders for admission cards at polypeptide.netvote.ch. The requisite login data is enclosed in the invitation supplied to shareholders. Shareholders may change any instructions they may have communicated electronically up to, but no later than, 23.59 (CEST) on 6 April 2026. Shareholders who exercise their voting rights online are asked not to additionally return their registration form by mail.

Language and translation service

The AGM 2026 will be held in German and English. Simultaneous translation into both languages will be available. Headsets will be provided in the foyer of the Chollerhalle.

Speakers' desk

Shareholders who wish to speak are kindly asked to notify the speakers' desk (*Wortmeldeschalter*) situated near the registration desk in the Chollerhalle before the AGM 2026 begins.

Questions

If shareholders have any questions about the AGM 2026, please contact PolyPeptide Investor Relations (investorrelations@polypeptide.com / +41 43 502 05 80) or the share register areg.ch ag (info@areg.ch / +41 62 209 16 60). If shareholders would like to report a change of address, please contact the share register areg.ch ag (info@areg.ch). Please note that changes of address should also be reported to the bank.

Light apéro

After the AGM 2026, all participants are cordially invited to attend a light apéro at the Chollerhalle.

Transport

We recommend that shareholders make the journey by public transport (www.sbb.ch/en) since parking options at the Chollerhalle are limited.

Attachments

- Registration form (with form for proxy and instructions to the Independent Proxy)
- Reply envelope

